Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
70.03
+1.83 (2.68%)
Oct 26, 2026, 4:00 PM EDT - Market closed
Tarsus Pharmaceuticals Employees
Tarsus Pharmaceuticals had 370 employees as of December 31, 2025. The number of employees increased by 47 or 14.55% compared to the previous year. That makes Tarsus Pharmaceuticals the 22,358th largest employer in the world and 2,917th in the United States.
Employees
370
Change (1Y)
47
Growth (1Y)
14.55%
Revenue / Employee
$1,638,732
Profits / Employee
-$125,611
Market Cap
3.07B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 370 | 47 | 14.55% |
| Dec 31, 2024 | 323 | 79 | 32.38% |
| Dec 31, 2023 | 244 | 157 | 180.46% |
| Dec 31, 2022 | 87 | 41 | 89.13% |
| Dec 31, 2021 | 46 | 26 | 130.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Telix Pharmaceuticals | 1,184 |
| Denali Therapeutics | 507 |
| Nurix Therapeutics | 317 |
| Dyne Therapeutics | 289 |
| Disc Medicine | 165 |
| Celcuity | 155 |
| Parabilis Medicines | 145 |
TARS News
- 13 days ago - Tarsus Pharmaceuticals files to sell 2.91M shares of common stock for holders - TheFly
- 27 days ago - Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting - GlobeNewsWire
- 4 weeks ago - Tarsus Pharmaceuticals resumed with a Buy at Goldman Sachs - TheFly
- 5 weeks ago - Tarsus Pharmaceuticals reinstated with an Overweight at Barclays - TheFly
- 6 weeks ago - Tarsus Pharmaceuticals price target raised to $105 from $88 at Jefferies - TheFly
- 7 weeks ago - Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - GlobeNewsWire
- 7 weeks ago - Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease - GlobeNewsWire
- 7 weeks ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire